Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desloratadine
Drug ID BADD_D00615
Description Desloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action. It is the active descarboethoxy metabolite of loratidine (a second generation histamine). Desloratidine has a long-lasting effect and does not cause drowsiness because it does not readily enter the central nervous system.
Indications and Usage For the relief of symptoms of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis. Desloratidine is also used for the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria.
Marketing Status Prescription
ATC Code R06AX27
DrugBank ID DB00967
KEGG ID D03693
MeSH ID C121345
PubChem ID 124087
TTD Drug ID D01GBY
NDC Product Code 53104-7613; 55111-073; 75895-0099; 65691-0057; 62993-0805; 62250-619; 51001-0034; 78206-119; 50090-4794; 53104-7688; 55111-551; 68180-153; 65015-698; 62756-481; 66039-830; 42291-240; 50090-3975; 55111-360; 50090-0765; 71335-1000; 62331-019; 66577-018; 69543-107
Synonyms desloratadine | descarboethoxyloratadine | SCH 34117 | SCH-34117 | Clarinex | Neoclarityn | Aerius | descarboethoxyloratadine acetate
Chemical Information
Molecular Formula C19H19ClN2
CAS Registry Number 100643-71-8
SMILES C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Insomnia19.02.01.002; 17.15.03.0020.007930%
Intentional self-injury19.12.01.002; 12.01.08.0360.006609%Not Available
Irritability19.04.02.013; 08.01.03.0110.003965%
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.002643%Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.003965%
Lip swelling07.05.04.005; 23.04.01.007; 10.01.05.0050.003965%Not Available
Local swelling08.01.03.0130.002643%Not Available
Metabolic acidosis14.01.01.0030.003965%Not Available
Mood swings19.04.03.001--Not Available
Movement disorder17.01.02.010--Not Available
Muscle spasms15.05.03.0040.002643%
Myalgia15.05.02.0010.002643%
Nasal congestion22.04.04.0010.002643%
Nasal septum perforation22.04.03.0030.002643%Not Available
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Oedema08.01.07.006; 14.05.06.0100.003965%Not Available
Otitis media11.01.05.004; 04.05.01.001--
Pain08.01.08.0040.003965%
Palpitations02.01.02.0030.005287%
Petit mal epilepsy17.12.04.0010.005287%Not Available
Pharyngeal oedema23.04.01.016; 22.04.05.003; 10.01.05.0160.002643%Not Available
Pharyngitis22.07.03.004; 07.05.07.004; 11.01.13.003--
Photosensitivity reaction23.03.09.0030.003965%
Pruritus23.03.12.0010.007930%
Psychomotor hyperactivity19.11.02.003; 17.01.02.011--Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Rash maculo-papular23.03.13.0040.003965%
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages